With deep experience in the life sciences industry, Michael W. Ryan advises manufacturers, healthcare providers, drug and technology developers, and investors on the legal, regulatory and reimbursement issues that arise during the development and commercialization of medical devices, clinical laboratory testing services, biological products and drugs. He guides life sciences companies and laboratories by evaluating and implementing strategies to optimize coding, coverage and payment for novel technologies. Michael also helps innovative companies identify and navigate applicable FDA regulatory requirements for new technologies, particularly in vitro diagnostics and digital health products. In particular, he regularly advises clients on the FDA’s evolving requirements for laboratory developed tests (LDTs) and digital health products, such as clinical decision support (CDS) software.
Throughout the life cycle of US Food and Drug Administration (FDA)-regulated medical devices, drugs and biological products, Michael provides clients, including global device companies, pharmaceutical companies and diagnostic test developers, with sound guidance on compliance issues. He is experienced in the review of promotional and marketing materials for FDA-regulated medical products.
Michael also counsels clinical laboratories on state and federal compliance issues, including those under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), state laboratory licensure laws, and billing and reimbursement rules.
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.